TipRanks
Adagene (DE:978)
FRANKFURT:978
Germany Market
978
Adagene
RESEARCH TOOLSreports

Adagene (978) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

978 Analyst Ratings

Strong Buy
5Ratings
Strong Buy
4 Buy
1 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Adagene
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

978 Stock 12 Month Forecast

Average Price Target

€7.61
▲(127.81% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Adagene in the last 3 months. The average price target is €7.61 with a high forecast of €8.95 and a low forecast of €6.27. The average price target represents a 127.81% change from the last price of €3.34.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","9":"€9","2.25":"€2.25","4.5":"€4.5","6.75":"€6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.9515017,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€8.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.608776445,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€7.61</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.26605119,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€6.27</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.25,4.5,6.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.74,3.217807823076923,3.695615646153846,4.1734234692307695,4.651231292307692,5.129039115384615,5.606846938461539,6.084654761538461,6.562462584615385,7.040270407692308,7.51807823076923,7.995886053846154,8.473693876923077,{"y":8.9515017,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.74,3.114521265,3.4890425300000003,3.863563795,4.23808506,4.612606325,4.98712759,5.361648855,5.736170120000001,6.110691385,6.48521265,6.8597339150000005,7.23425518,{"y":7.608776445,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.74,3.011234706923077,3.282469413846154,3.553704120769231,3.824938827692308,4.096173534615385,4.367408241538461,4.638642948461539,4.909877655384616,5.181112362307692,5.452347069230769,5.723581776153846,5.994816483076923,{"y":6.26605119,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.64,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.579,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.64,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.64,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.94,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.639,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.14,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.98,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.74,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€8.95Average Price Target€7.61Lowest Price Target€6.27
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:978
Arthur He CFA
H.C. Wainwright
H.C. Wainwright
€6.27
Buy
87.61%
Upside
Reiterated
10/19/26
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (NASDAQ: JANX), Sarepta Therapeutics (NASDAQ: SRPT) and Adagene (NASDAQ: ADAG)
LifeSci Capital Analyst forecast on DE:978
Charles Zhu
LifeSci Capital
LifeSci Capital
€7.16
Buy
114.41%
Upside
Reiterated
09/29/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), Adagene (NASDAQ: ADAG) and Inventiva (NASDAQ: IVA)
Chardan Capital Analyst forecast on DE:978
Gautam Chukka
Chardan Capital
Chardan Capital
€8.06
Buy
141.21%
Upside
Initiated
09/10/26
Adagene initiated with a Buy at ChardanAdagene initiated with a Buy at Chardan
Guggenheim Analyst forecast on DE:978
Paul Jeng
Guggenheim
Guggenheim
€8.95
Buy
168.01%
Upside
Reiterated
09/10/26
Analysts' Top Healthcare Picks: Adagene (ADAG), AbbVie (ABBV)
Morgan Stanley Analyst forecast on DE:978
Maxwell Skor
Morgan Stanley
Morgan Stanley
―
Hold
―
Reiterated
08/17/26
Analysts Offer Insights on Healthcare Companies: Adagene (NASDAQ: ADAG) and Natera (NASDAQ: NTRA)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:978
Arthur He CFA
H.C. Wainwright
H.C. Wainwright
€6.27
Buy
87.61%
Upside
Reiterated
10/19/26
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (NASDAQ: JANX), Sarepta Therapeutics (NASDAQ: SRPT) and Adagene (NASDAQ: ADAG)
LifeSci Capital Analyst forecast on DE:978
Charles Zhu
LifeSci Capital
LifeSci Capital
€7.16
Buy
114.41%
Upside
Reiterated
09/29/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), Adagene (NASDAQ: ADAG) and Inventiva (NASDAQ: IVA)
Chardan Capital Analyst forecast on DE:978
Gautam Chukka
Chardan Capital
Chardan Capital
€8.06
Buy
141.21%
Upside
Initiated
09/10/26
Adagene initiated with a Buy at ChardanAdagene initiated with a Buy at Chardan
Guggenheim Analyst forecast on DE:978
Paul Jeng
Guggenheim
Guggenheim
€8.95
Buy
168.01%
Upside
Reiterated
09/10/26
Analysts' Top Healthcare Picks: Adagene (ADAG), AbbVie (ABBV)
Morgan Stanley Analyst forecast on DE:978
Maxwell Skor
Morgan Stanley
Morgan Stanley
―
Hold
―
Reiterated
08/17/26
Analysts Offer Insights on Healthcare Companies: Adagene (NASDAQ: ADAG) and Natera (NASDAQ: NTRA)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AXGNAxoGen
SIBNSI-Bone
AORTArtivion
PHVSPharvaris
HELPHelus Pharma
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Adagene

3 Months
Charles ZhuLifeSci Capital
Success Rate
4/8 ratings generated profit
50%
Average Return
+25.55%
Copying Charles Zhu's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +25.55% per trade.
1 Year
Arthur He CFAH.C. Wainwright
Success Rate
11/18 ratings generated profit
61%
Average Return
+28.95%
Copying Arthur He CFA's trades and holding each position for 1 Year would result in 61.11% of your transactions generating a profit, with an average return of +28.95% per trade.
2 Years
Arthur He CFAH.C. Wainwright
Success Rate
15/18 ratings generated profit
83%
Average Return
+21.29%
Copying Arthur He CFA's trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +21.29% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

978 Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
6
2
3
8
8
Buy
0
0
0
0
0
Hold
0
0
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
2
4
9
9
In the current month, 978 has received 8 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 978 average Analyst price target in the past 3 months is 7.61.
Each month's total comprises the sum of three months' worth of ratings.

978 Financial Forecast

978 Earnings Forecast

Next quarter’s earnings estimate for 978 is -€0.19 with a range of -€0.20 to -€0.18. The previous quarter’s EPS was -€0.23. 978 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 978 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 978 is -€0.19 with a range of -€0.20 to -€0.18. The previous quarter’s EPS was -€0.23. 978 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 978 has Performed in-line its overall industry.

978 Sales Forecast

Next quarter’s sales forecast for 978 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €1.44M. 978 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 978 has Performed in-line its overall industry.
Next quarter’s sales forecast for 978 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €1.44M. 978 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 978 has Performed in-line its overall industry.

978 Stock Forecast FAQ

What is DE:978’s average 12-month price target, according to analysts?
Based on analyst ratings, Adagene’s 12-month average price target is 7.61.
    What is DE:978’s upside potential, based on the analysts’ average price target?
    Adagene has 127.81% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Adagene a Buy, Sell or Hold?
          Adagene has a consensus rating of Strong Buy, which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Adagene’s share price target?
            The average share price target for Adagene is 7.61. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €8.95 ,and the lowest forecast is €6.27. The average share price target represents 127.81% Increase from the current price of €3.34.
              What do analysts say about Adagene?
              Adagene’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of Adagene?
                To buy shares of DE:978, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.